February 19, 2026 – Novartis AG has notified the Board of Novartis India Limited (“NIL”), a company listed on BSE Limited, that Novartis AG has entered into an agreement with the ChrysCapital group (“ChrysCapital”), one of the largest private equity firms investing in India, to transfer its 70.68% shareholding in NIL. This divestment follows a strategic review announced and conducted by Novartis AG starting February 2024.
The closing of the transaction is subject to the satisfaction of certain conditions precedent and is expected to close in Q3 2026.
The Board of NIL was informed of the decision by Novartis AG to transfer its shareholding following the signature today between Novartis AG and ChrysCapital.
Upon completion of this transfer of shares, Novartis will complete its transformation into a pure-play innovative medicines company and continues to adapt its footprint for efficient, sustainable long-term growth aligned with its global strategy.
Information about Novartis in India
Novartis will continue its presence in India through Novartis Healthcare Private Limited (NHPL), a wholly owned subsidiary of the Novartis group in India. NHPL includes the commercial arm of Novartis in India, the Novartis Corporate Center in Hyderabad, and R&D teams, which currently conduct clinical trials at more than 300 trial sites in the country. Aligned with our global strategy, we are expanding our innovative Cardio Renal Metabolic and Oncology portfolio, marked by recent launches and a strong pipeline of innovative medicines for India.
Novartis India Limited (NIL), an independent public company listed on BSE Limited, is separate from Novartis Healthcare Private Limited. The transfer of Novartis AG shareholding in NIL will not impact Novartis Healthcare Private Limited operations.
Novartis remains deeply committed to India with a footprint that has expanded significantly in recent years and today Novartis proudly employs more than 9,000 associates in India. For more information about Novartis in India, explore https://www.novartis.com/in-en/ .
For media enquiries, please contact:
Vaishali Iyer
Email: [email protected]
Aditi Roy Email: [email protected]